|
- 现金
- 62111 元
- 精华
- 26
- 帖子
- 30441
- 注册时间
- 2009-10-5
- 最后登录
- 2022-12-28
|
J&J deepens its antiviral pipeline with Novira buyout
By Damian Garde Comment | Forward | Twitter | Facebook | LinkedIn
Johnson & Johnson ($JNJ) is trading an undisclosed sum for private drugmaker Novira Therapeutics, picking up an early-stage treatment for hepatitis B and a handful of antivirals.
With the buyout, expected to close in the fourth quarter, J&J gets NVR 3-778, a Phase II-ready hep B therapy that attacks the virus' capsid protein to disrupt the process of viral reproduction. In Phase Ia results disclosed last year, Novira's lead drug demonstrated itself safe and tolerable in 40 healthy patients, the company said, setting the stage for a Phase II efficacy study. The goal is to take a page from hep C treatments from Gilead Sciences ($GILD) and others by going beyond viral suppression and offering functional cure rates, Novira said.
Beyond NVR 3-778, Novira has a second-generation capsid protein inhibitor now in preclinical development, plus a cccDNA blocker in the lead-optimization stage, the company said.
Lawrence Blatt
For J&J, the deal is an effort to follow through on its $1.75 billion, all-cash acquisition of Alios BioPharma last year, a deal that expanded its antiviral pipeline by adding treatments for respiratory syncytial virus and hep C. Integrating Alios, J&J appointed the company's CEO, Lawrence Blatt, to head its infectious disease business. Now Blatt will inherit Novira's pipeline, steering J&J's antiviral efforts as the company seeks to catch up with its rivals in the field.
"Combining Novira's recent breakthroughs with our vast experience in viral diseases we endeavor to deliver novel medicines for patients suffering from this insidious disease," Blatt said in a statement.
Novira was founded in 1999 and closed a $25 million A round in 2013 with cash from Versant Ventures, 5AM Ventures, Canaan Partners and others.
强生公司加深其抗病毒的管道与Novira买断
通过达米安前卫评论|转发|微博| Facebook的| LinkedIn
强生公司（JNJ $）的交易金额不详私营制药商Novira治疗，拿起一个早期治疗乙肝和一些抗病毒药物。
随着收购，预计将在今年第四季度，强生公司获得NVR 3-778，第二阶段准备的乙肝治疗方法，攻击病毒的衣壳蛋白破坏病毒的复制过程。在披露去年1a期结果，Novira的先导药物表现出自身的安全和可容忍的40名健康的病人，该公司表示，设置阶段为第二阶段的疗效研究。我们的目标是超越抑制病毒，并提供功能治愈率采取从Gilead Sciences公司（$ GILD）和其他丙肝治疗的页面，Novira说。
除了NVR 3-778，Novira现在有一个第二代衣壳蛋白抑制剂在临床前开发阶段，加上在铅优化阶段cccDNA的拦截，该公司表示。
劳伦斯·布拉特
对于强生，这笔交易是为了贯彻其$ 1.75十亿，全现金收购Alios生物制药，去年一个协议，通过增加治疗呼吸道合胞病毒和HEP C.整合Alios，J＆J任命为扩大其抗病毒管道公司的首席执行官劳伦斯·布拉特，负责其传染病的业务。现在，布拉特将继承Novira的管道，转向强生的抗病毒的努力，该公司试图追赶其在该领域的竞争对手。
“结合Novira最近的突破与我们的病毒性疾病，我们努力提供新的药物对患者从这个阴险的疾病的患者的丰富经验，”布拉特在一份声明中说。
Novira成立于1999年，并关闭了$ 2500万圆，2013年与Versant的风险投资公司，5AM风险投资公司，Canaan Partners公司和其他现金。
Google Translate for Business:Translator ToolkitWebsite TranslatorG |
|
楼主: HBVCURER
发表于 2015-11-5 20:00
